{
    "clinical_study": {
        "@rank": "11667", 
        "acronym": "AXEPT", 
        "arm_group": [
            {
                "arm_group_label": "FOLFIRI +/- Bevacizumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3"
            }, 
            {
                "arm_group_label": "XELIRI +/- Bevacizumab", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to determine the non-inferiority of overall survival\n      XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as\n      Second-line therapy in Patient with Metastatic Colorectal Cancer."
        }, 
        "brief_title": "A Phase III Study of 2nd-line XELIRI \u00b1 Bevacizumab vs. FOLFIRI \u00b1 Bevacizumab in mCRC", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Neoplasms", 
            "Neoplasm Metastasis", 
            "Intestinal Neoplasms", 
            "Gastrointestinal Neoplasms", 
            "Digestive System Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms", 
                "Digestive System Neoplasms", 
                "Gastrointestinal Neoplasms", 
                "Intestinal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary endpoint: Overall survival (OS), Secondary endpoints: Progression-free survival\n      (PFS), Time to treatment failure (TTF), Overall response rate (ORR),Disease Control Rate\n      (DCR), Relative dose intensity, Safety, and Correlation between UGT1A1 genotype and Safety."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically-confirmed inoperable colorectal adenocarcinoma excluding vermiform\n             appendix cancer and anal canal cancer.\n\n          2. Age \u226520 years at the time of informed consent\n\n          3. ECOG performance status (PS) of 0-2\n\n          4. Written informed consent prior to study-specific screening procedures\n\n          5. Life expectancy of at least 90 days\n\n          6. Withdrawal from first-line chemotherapy (regardless of containing molecular-targeted\n             drugs) for metastatic colorectal cancer due to intolerable toxicity or progressive\n             disease, or relapse within 180 days after the last dose of adjuvant chemotherapy.\n\n          7. Adequate organ function according to following laboratory values obtained within 14\n             days before enrolment (excluding patients who received blood transfusions or\n             hematopoietic growth factors within 14 days before the laboratory test) Neutrophil\n             count: \u22651500/mm3 Platelet count: \u226510.0 x 104/mm3 Hemoglobin: \u22659.0 g/dL Total\n             bilirubin: \u22641.5 mg/dL AST, ALT:  \u2264100 IU/L (\u2264200 IU/I if liver metastases present)\n             Serum creatinine: \u22641.5 mg/dL\n\n        Exclusion Criteria:\n\n          1. History of other malignancy with a disease-free interval <5 years (other than\n             curatively treated cutaneous basal cell carcinoma, curatively treated carcinoma in\n             situ of the cervix, and gastroenterological cancer confirmed to be cured by\n             endoscopic mucosal resection)\n\n          2. With massive pleural effusion or ascites requiring intervention\n\n          3. Radiological evidence of brain tumor or brain metastases\n\n          4. Active infection including hepatitis\n\n          5. Any of the following complication:\n\n             i) Gastrointestinal bleeding or gastrointestinal obstruction (including paralytic\n             ileus) ii) Symptomatic heart disease (including unstable angina, myocardial\n             infarction, and heart failure) iii) Interstitial pneumonia or pulmonary fibrosis iv)\n             Uncontrolled diabetes mellitus v) Uncontrolled diarrhea (that interferes with daily\n             activities despite adequate therapy)\n\n          6. Any of the following medical history:\n\n             Myocardial infarction: History of one episode within one year before enrollment or\n             two or more lifetime episodes i) Serious hypersensitivity to any of the study drugs\n             ii) History of adverse reaction to fluoropyrimidines suggesting dihydropyrimidine\n             dehydrogenase (DPD) deficiency\n\n          7. Previous treatment with irinotecan hydrochloride\n\n          8. Current treatment with atazanavir sulfate\n\n          9. Previous treatment with tegafur, gimeracil, and oteracil potassium within seven days\n             before enrollment\n\n         10. Pregnant or lactating females, and males and females unwilling to use contraception\n\n         11. Requires continuous treatment with systemic steroids\n\n         12. Psychiatric disability that would preclude study compliance\n\n         13. Otherwise determined by the investigator to be unsuitable for participation in the\n             study\n\n         14. Concurrent gastrointestinal perforation or history of gastrointestinal perforation\n             with 1 year before enrollment\n\n         15. History of pulmonary hemorrhage/hemoptysis \u2265 Grade 2 (defined as bright red blood of\n             at least 2.5mL) within 1 month prior to enrollment.\n\n         16. History of laparotomy, thoracotomy, or intestinal resection within 28 days before\n             enrollment\n\n         17. Unhealed wound (except suture wounds from implantation of a central venous port),\n             gastrointestinal ulcer, or traumatic fracture\n\n         18. Current or recent (within 1 year) thromboembolism or cerebrovascular disease\n\n         19. Currently receiving or requires anticoagulation therapy (> 325 mg/day of aspirin)\n\n         20. Bleeding diathesis, coagulopathy, or coagulation factor abnormality (INR \u22651.5 within\n             14 days before enrollment)\n\n         21. Uncontrolled hypertension\n\n         22. Urine dipstick for proteinuria >+2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996306", 
            "org_study_id": "AXEPT", 
            "secondary_id": "UMIN000012263"
        }, 
        "intervention": [
            {
                "arm_group_label": "FOLFIRI +/- Bevacizumab", 
                "description": "5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Biological", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "FOLFIRI +/- Bevacizumab", 
                "description": "150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.", 
                "intervention_name": "CPT-11 (Irinotecan)", 
                "intervention_type": "Drug", 
                "other_name": "Irinotecan"
            }, 
            {
                "arm_group_label": "FOLFIRI +/- Bevacizumab", 
                "description": "400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.", 
                "intervention_name": "5-FU Bolus", 
                "intervention_type": "Drug", 
                "other_name": "fluorouracil"
            }, 
            {
                "arm_group_label": "FOLFIRI +/- Bevacizumab", 
                "description": "2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.", 
                "intervention_name": "5-FU Infusion", 
                "intervention_type": "Drug", 
                "other_name": "fluorouracil"
            }, 
            {
                "arm_group_label": "FOLFIRI +/- Bevacizumab", 
                "description": "200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.", 
                "intervention_name": "l-LV (dl-LV)", 
                "intervention_type": "Drug", 
                "other_name": "Leucovorin"
            }, 
            {
                "arm_group_label": "XELIRI +/- Bevacizumab", 
                "description": "7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.", 
                "intervention_name": "bevacizumab", 
                "intervention_type": "Biological", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "XELIRI +/- Bevacizumab", 
                "description": "150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.", 
                "intervention_name": "CPT-11 (Irinotecan)", 
                "intervention_type": "Drug", 
                "other_name": "Irinotecan"
            }, 
            {
                "arm_group_label": "XELIRI +/- Bevacizumab", 
                "description": "1600mg/m2/day  oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Capecitabine", 
                "Irinotecan", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AXEPT", 
            "Fluorouracil", 
            "CPT-11", 
            "XELIRI", 
            "Bevacizumab", 
            "FOLFIRI", 
            "Capecitabine", 
            "2nd-line metastatic colorectal cancer"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "contact": {
                "email": "axept@ecrin.or.jp", 
                "last_name": "Junichi Sakamoto, MD,PhD,FACS", 
                "phone": "+81-75-762-1200"
            }, 
            "facility": {
                "address": {
                    "city": "Kyoto", 
                    "country": "Japan", 
                    "zip": "606-8392"
                }, 
                "name": "NPO Epidemiological and Clinical Research Information Network (ECRIN)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "axept@ecrin.or.jp", 
            "last_name": "Junichi Sakamoto, MD,PhD,FACS", 
            "phone": "+81-75-762-1200"
        }, 
        "overall_official": [
            {
                "affiliation": "National Cancer Center Hospital, Japan", 
                "last_name": "Yasuhide Yamada, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ASAN Medical center, South Korea", 
                "last_name": "Tae Won Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center, South Korea", 
                "last_name": "Young Suk Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Sun Yat-Sen University Cancer Center, China", 
                "last_name": "Ruihua Xu, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time from the date of enrollment to death from any cause.", 
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "Assessed until 1.5 years  after the last patient enrolment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from the date of enrollment to the earlier of the date of confirmed progression or death from any cause.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Assessed until 1.5 years  after the last patient enrolment"
            }, 
            {
                "description": "Time from the date of enrollment to the earlier of the date of confirmed progression, death from any cause, or discontinuation of protocol treatment.", 
                "measure": "Time to treatment failure (TTF)", 
                "safety_issue": "No", 
                "time_frame": "Assessed until 1.5 years  after the last patient enrolment"
            }, 
            {
                "description": "Proportion of eligible patients with measurable lesions with a best overall response of CR or PR assessed by the attending physician.", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 6, 12 week and thereafter every 8 weeks"
            }, 
            {
                "description": "Proportion of best overall response of CR, PR, or SD assessed by the attending physician.", 
                "measure": "Disease Control Rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 6, 12 week and thereafter every 8 weeks"
            }, 
            {
                "description": "will be calculated for each drug to evaluate treatment compliance in the all-treated population during the observation period.", 
                "measure": "Relative Dose Intensity", 
                "safety_issue": "No", 
                "time_frame": "Assessed until final dosing to the last patient"
            }, 
            {
                "description": "The incidence of worst-grade adverse events (toxicities) on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm in all treated patients for the following events.", 
                "measure": "Incidence of Adverse Events (Adverse Reactions)", 
                "safety_issue": "Yes", 
                "time_frame": "Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery"
            }, 
            {
                "description": "The incidence of worst-grade adverse events on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm and UGT1A1 genotype in all treated patients with a known UGT1A1 genotype profile", 
                "measure": "Correlation between UGT1A1 genotype and safety", 
                "safety_issue": "Yes", 
                "time_frame": "Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery"
            }
        ], 
        "source": "Epidemiological and Clinical Research Information Network", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Epidemiological and Clinical Research Information Network", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}